tbuckley/cabot-search huggingface dataset:
The Incidence of Bone Metastases and Skeletal-Related Events in Breast Cancer Patients: A Population-Based Cohort Study in Denmark (1999 – 2007).
Authors: M. Yong, A. Jensen, J. Jacobsen, M. Nørgaard, J. Fryzek, H. Sørensen
Journal: Cancer Research (2009)

Abstract Background Breast cancer (BrCa) is the most commonly diagnosed cancer among women in the industrialized world. More than half of women presenting with metastatic BrCa develop bone metastases. Bone metastases increase the risk of skeletal-related events (SREs), defined as radiation to bone, pathologic fractures, spinal cord compression, bone surgery, or altered antineoplastic therapy to treat bone pain. Both bone metastases and SREs are associated with unfavorable prognosis and greatly affect quality of life. To date, the epidemiology of the subgroup of BrCa patients who develop bone metastases and/or SREs has not been well-characterized. Our objective was to estimate the one- and five-year incidence of bone metastases and SREs in a large population cohort of newly-diagnosed BrCa patients in Denmark (population ∼ 5.4 million inhabitants). Methods We identified women diagnosed with BrCa (International Classification of Diseases, 10th Revision (ICD-10) code C50.x.) from January 1, 1999 through December 31, 2007, with follow-up through April 2008. We retrieved this data from Denmark's National Registry of Patients (NRP), which includes records from all Danish hospitals. We also identified bone metastases (ICD-10 code C79.5) and recorded SREs. The Kaplan-Meier method was used to estimate time to bone metastases and time to first SRE. We also calculated 1- and 5-year incidence rates (IR) of bone metastases and first SRE in newly-diagnosed BrCa patients. Results We identified 35,941 BrCa patients from the NRP. The median age at diagnosis was 62 years (range, 18-104 years). A total of 1,494 (4%) patients developed bone metastases during follow-up, and of these, 712 developed an SRE. The distribution of SREs by type were 394 (55%) with radiation to the bone, 133 (19%) with pathological or osteoporotic fracture, 42 (6%) with bone surgery, and 143 (20%) with spinal cord compression. The 1-year IR of bone metastases was 13.7 [95% confidence interval (CI): 12.5-15.0] per 1000 person-years (P-Y). The 1-year IR of SREs among patients with bone metastases was 55 times that of the 1-year IR of bone metastases in BrCa patients at 759.2 (95% CI: 662.0-870.5) per 1000 P-Y. After five years of follow-up, the incidence curves plateaued at approximately 4% and 48% for bone metastases and SREs, respectively (Figures 1 and 2). Conclusions Among breast cancer patients with bone metastases, there was a strong tendency towards development of SREs within a year of bone metastases diagnosis; however, this phenomenon stabilized beyond 5 years of bone metastases diagnosis. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2051.
ATRIAL NATRIURETIC PEPTIDE AS A PREDICTOR OF ATRIAL FIBRILLATION IN A MALE POPULATION STUDY: THE STUDY OF MEN BORN IN 1913
Authors: Zacharias Mandalenakis, Henry Eriksson, Mikael Dellborg, Kenneth Caidahl, Lennart Welin, Kurt Svärdsudd, Saga Johansson, Georgios Lappas, Annika Rosengren, Per-Olof Hansson
Journal: Journal of the American College of Cardiology (2013)
Neuroleptic responsivity of negative and positive symptoms in schizophrenia
Authors: A Breier, O M Wolkowitz, A R Doran, A Roy, J Boronow, D W Hommer, D Pickar
Journal: American Journal of Psychiatry (1987)

The authors prospectively examined the effects of double-blind, placebo-controlled neuroleptic withdrawal and administration on ratings of negative and positive symptoms in 19 young patients with chronic schizophrenia. Negative symptoms were significantly reduced by neuroleptic treatment, and negative and positive symptoms demonstrated similar patterns of reduction and exacerbation during neuroleptic treatment and withdrawal, respectively. The changes in negative and positive symptoms induced by neuroleptic treatment and withdrawal were not significantly correlated, however. The negative and positive symptom profiles of individual patients were significantly altered by neuroleptic treatment, indicating limitations to the cross-sectional classification of patients on the basis of predominance of one or the other symptom group. The authors discuss implications for the neurobiological underpinnings of negative and positive symptoms.
Abstract 1494: The role of microenvironment in mammary epithelial cell plasticity
Authors: Ana Luisa Correia, Hidetoshi Mori, Fernando C. Schmitt, Mina J. Bissell
Journal: Cancer Research (2011)

Abstract Understanding breast cancer heterogeneity is crucial for the development of targeted therapeutic interventions. One source of this intratumoral diversity comes from changes induced in epithelial cells by signals they receive from the stromal microenvironment. These changes include the epithelial-to-mesenchymal transition (EMT), a process of cellular plasticity by which epithelial cells disengage cell-cell and cell-extracellular matrix interactions, alter cytoskeletal structure, and implement a transcriptional program that facilitates the acquisition of aggressive traits, such as increased motility, invasiveness and resistance to apoptosis. Bissell lab has demonstrated that an extracellular protease, matrix metalloproteinase-3 (MMP3), is able to initiate the formation of mammary tumors in mice, as well as trigger EMT in mammary epithelial cells when activated. Furthermore, the observed EMT in MMP3-overexpressing cells was found to be dependent upon reactive oxygen species (ROS) production. However, it is not clear how this extracellular secreted protein functions with an epithelial cell to affect its intracellular events. To understand the mechanism by which MMP3 drives transformation of mammary cells, we asked which domain of MMP3 is required for ROS production or EMT in mammary epithelial cells, and we are investigating cell surface proteins that may be target of degradation or binding partner of MMP3 during tumorigenesis. This work will unravel new candidates for specific inhibition, providing attractive options for treatment of this and other diseases in which MMP3 plays a pathological role. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1494. doi:10.1158/1538-7445.AM2011-1494
TCTAP C-172 Endovascular Therapy for Persistent Sciatic Artery Occlusion Using Carbon Dioxide Digital Subtraction Angiography
Authors: Nobuhito Kaneko, Teppei Murata, Yoshifumi Kubo, Noboru Kagawa, Masao Kuwada, Yusuke Souma, Takayuki Tatebayashi, Sakashi Noji
Journal: Journal of the American College of Cardiology (2015)
AB0598 Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results from A Russian Registry (NORMA): Table 1.
Authors: T. Beketova, E. Alexandrova, T. Novoselova, E. Sazhina, E. Nikolaeva, A. Smirnov, V. Sorotskaya, E. Zemerova, I. Nam, N. Nikitina, G. Arkhangelskaya, Z. Bagautdinova, I. Dashkov, S. Chernykh, O. Zhirnova, Y. Lushpaeva, L. Masneva, I. Afanasjeva, A. Arsenyev, I. Kondratenko, I. Bashkova, S. Glukhova, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Rituximab (RTX) therapy is a treatment option in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. <h3>Objectives</h3> Analysis of safety and efficacy of RTX in patients with ANCA-associated vasculitis treated in fourteen Russian clinical centers. <h3>Methods</h3> In 2011, Nasonova V.A. Research Institute of Rheumatology and Association of Rheumatologists of Russia created the NORMA project, a multicenter study whose objective is to gather information concerning the use of RTX in adult patients with systemic autoimmune diseases. <h3>Results</h3> 50 patients with ANCA-associated vasculitis treated with RTX are included in the NORMA registry (26 women and 24 men, mean age 40±15 years), including 35 patients with granulomatosis with polyangiitis, 13 with microscopic polyangiitis, 2 with eosinophilic granulomatosis with polyangiitis. 39 patients were cANCA/PR3 positive and 11 pANCA/MPO positive. 34% of patients had refractory ANCA-associated vasculitis, 36% high activity and/or signs of poor prognosis and 28% intolerance of standard agents. 25/50 patients were re-treatment at low-dose RTX (≤1000 mg) for partial responses/relapses (70%) or to maintain remission (30%). A total of 46 RTX subsequent cycles were completed, intervals between cycles averaged 6.4 months (range 4.5-11.3). Among 25 patients followed for more than 12 months, 23 complete and 2 partial responses were observed. Table 1 shows Birmingham vasculitis activity score (BVAS), CD19+ B-cells in peripheral blood and serum IgG levels at enrolment and after RTX treatment. Re-treatment was effective in controlling disease activity and did not result in progressive reduction in IgG. Ten patients (20%) had serious adverse events (including 6 infections and 3 neutropenia), all received a single cycle of RTX. Five patients died, two due to pneumonia and late onset neutropenia, two due to acute pulmonary embolism and one patient due to refractory vasculitis and pneumonia. <h3>Conclusions</h3> This uncontrolled observational study shows good tolerance and clinical efficacy of RTX in patients with ANCA-associated vasculitis and suggest, that low-dose RTX for the re-treatment is also effective. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1960
Gastric amyloidosis: unusual cause of upper gastrointestinal hemorrhage
Authors: M. Marques, J. Sarmento, S. Rodrigues, S. Guimarães, E. Fonseca, G. Macedo
Journal: Endoscopy (2011)

A 55-year-old man with multiple myeloma was admitted with hematemesis. After resuscitation, patient underwent endoscopy, which revealed a large vegetative mass covered by whitish plaques in the body/antrum transition of the greater curvature, with oozing bleeding ([Fig. 1]); the gastric walls were also covered by similar whitish lesions. Hemostasis with epinephrine injection was successful, and biopsy samples were taken. Pathology revealed chronic gastritis negative for Helicobacter pylori infection, fibrino-necrotic exudates, indicative of ulceration of gastric mucosa, and abundant eosinophilic and hyaline deposits which were positive for amyloid substance ([Fig. 2]).
AB1200 Cognitive impairment associated with S100β protein in childhood-onset systemic lupus erythematosus
Authors: H. Aldar, A.T. Lapa, B. Belini, N.A. Sinicato, M. Postal, P. Fernandes, R. Marini, S. Appenzeller
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To determine clinical and laboratorial manifestations associated with S100β protein in childhood-onset systemic lupus erythematosus (cSLE) patients <h3>Methods</h3> We included consecutive cSLE patients with disease onset before the age of 16 and healthy controls and age and healthy age and sex matched controls. All subjects underwent a standardized neuropsychological evaluation assessing the following: simple attention, complex attention, memory, visuospatial processing, language, reasoning/problem solving, psychomotor speed, and executive functions. Individual results were converted into standard scores and compared to normative data. Subjects with a total score in any of the 8 domains ≤-2 SD below the normative value were considered impaired. Mood disorders were determined through Becks Depression and Becks Anxiety Inventory (BDI and BAI) in all subjects. cSLE patients were assessed for disease activity [SLE Disease Activity Index (SLEDAI)], damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)] and current drug exposures. S100β protein levels were measured by enzyme-linked immunosorbent assay using commercial kits. Clinical/laboratorial manifestations, disease activity, cumulative damage and drugs undertaken were assessed at time of blood withdrawal. <h3>Results</h3> We included 42 cSLE patients (mean age 16.56±3.68) and 20 healthy controls (mean age 19.9±5.31). Cognitive impairment was observed in 25 (60%) cSLE patients and in 3 (15%) healthy controls (p&lt;0.05). Patients with cognitive impairment presented significantly higher levels of the S100β protein (median 38.64) compared to patients without cognitive impairment (median 25.49; p=0.001) and controls (median 23.62; p&lt;0.001). No other clinical/laboratorial manifestations and drugs undertaken were associated to S100β protein levels in cSLE. <h3>Conclusions</h3> Cognitive impairment was associated with higher levels of the S100β protein, suggesting the presence of neuronal lesions in this cSLE patients cohort. <h3>Disclosure of Interest</h3> H. Aldar Grant/Research support from: FAPESP 2009/13046-3, A. Lapa Grant/Research support from: FAPESP 2010/13639-1, B. Belini Grant/Research support from: FAPSEP 2009/12343-4, N. Sinicato Grant/Research support from: FAPESP 2010/13637-9, M. Postal Grant/Research support from: FAPESP 2009/11076-2, P. Fernandes: None Declared, R. Marini: None Declared, S. Appenzeller Grant/Research support from: FAPESP 2008/02917-0; Conselho Nacional Pesquisa Desenvolvimento-Brasil CNPq (300447/2009-4)
Intermittent Therapy with L-Thyroxine
Authors: Robert S. Bernstein, Jacob Robbins
Journal: New England Journal of Medicine (1969)

Two athyreotic patients and five patients on suppressive doses of L-thyroxine (L-T4) were studied with intermittent oral therapy given as a single weekly dose. Thyroid tests were compared during intermittent therapy of 2.0 mg weekly and during daily therapy with 0.3 mg of L-T4. Serum thyroxine levels were significantly lower on intermittent therapy in three of seven patients. Nevertheless, five of five patients showed complete suppression of 131I uptake by the thyroid gland one week after the dose of thyroxine. All patients were clinically euthyroid, and there was no difference in serum cholesterol. There were no toxic symptoms even after a single oral dose of 2.5 mg of L-T4. Intermittent therapy proved to be an effective means of thyroid replacement.
Detection of Chronic Recurrent Lower Extremity Deep Venous Thrombosis on Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography
Authors: KEVIN J. CHANG, HONGMING ZHUANG, ABASS ALAVI
Journal: Clinical Nuclear Medicine (2000)

A 48-year-old woman with a history of a neuroendocrine small cell tumor of the uterus with involvement of the lymph nodes of the right groin underwent abdominal hysterectomy, oophorectomy, and chemotherapy with a good clinical response. A deep venous thrombosis of her right leg first developed 3 months before she was examined in the nuclear medicine department and was anticoagulated successfully. She has had complete resolution of all adenopathy, with mild right thigh firmness without residual swelling or tenderness. Positron emission tomography with fluorine-18 fluorodeoxyglucose (FDG PET) was performed to rule out metastases. No evidence of active neoplastic disease was found, but an area of intense tracer uptake in the right calf was detected, consistent with inflammation from chronic thrombophlebitis. Inflammatory vascular disorders have been detected by FDG PET in the past, and this case report suggests that FDG PET may assume a role in detecting thrombophlebitis.
Long-Term Risk of Breast Cancer in Women with Fibroadenoma
Authors: William D. Dupont, David L. Page, Fritz F. Parl, Cindy L. Vnencak-Jones, Walton D. Plummer, Margaret S. Rados, Peggy A. Schuyler
Journal: New England Journal of Medicine (1994)

Fibroadenomas are benign breast tumors that are commonly diagnosed in young women and are associated with a slight increase in the risk of breast cancer. These lesions vary considerably in their histologic characteristics. We assessed the correlation between the histologic features of fibroadenomas and the risk of subsequent breast cancer.
Challenging the “Culture of Culturing”
Authors: Heidi L. Wald
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Size characteristics of larger academic human environmental health programs in the United States.
Authors: B D Goldstein, M G Robson, C E Botnick
Journal: Environmental Health Perspectives (1998)

We have performed a benchmark exercise evaluating larger academic programs in human environmental health sciences. These programs are located at schools of public health and at other institutions that have NIEHS Centers of Excellence. The largest programs were those in which there was both an NIEHS center and a public health graduate education program. This suggests that there is synergy between environmental health sciences research and involvement in public and community health.
Abstract 2616: Association of <i>UGT2B17</i> gene copy number variation with breast cancer risk: The Nashville Breast Health Study
Authors: Guoliang Li, Sandra L. Deming, Qiuyin Cai, Alecia M. Fair, Martha J. Shrubsole, Xiao Ou Shu, Mark Kelley, Wei Zheng
Journal: Cancer Research (2012)

Abstract UDP-glucuronosyltransferase 2B17 (UGT2B17) catalyzes the transfer of glucuronic acid from uridine diphosphoglucuronic acid to a variety of substrates, including estrogen, a hormone that plays an important role in the etiology of breast cancer. Glucuronidated estrogens are more polar and water soluble; thus, they are more easily excreted in the bile and urine. The UGT2B17 gene displays variations in copy number (0 copies, 1 copy, and 2 copies), and the null genotype (0 copies) is associated with lower glucuronidating activity in human liver microsomes. In this study, we evaluated the association of UGT2B17 gene copy number variation with breast cancer risk. Included in the study were 1,536 breast cancer cases and 1,205 matched controls recruited into the Nashville Breast Health Study, a population-based, case-control study based in Nashville, Tennessee. Copy number of the UGT2B17 gene was evaluated by real-time PCR by using ABI's TaqMan Copy Number Assays reagents. UGT2B17 gene copy number variation was associated with breast cancer risk with odds ratios of 1.17 (95% CI: 1.00-1.38) and 1.33 (95% CI: 1.02-1.74), respectively, for 1 and 0 copies of the UGT2B17 gene, compared with 2 copies of the gene. The association varied little by menopausal status. The association was consistent in both whites and African Americans. Our study suggests that UGT2B17 gene copy number variation may play a role in the etiology of breast cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2616. doi:1538-7445.AM2012-2616
PMO-228 Vitamin D deficiency in a cohort of IBD patients treated with anti-TNFα therapy
Authors: C R Parris, D R Gaya, J Winter, J Munro, A J Morris
Journal: Gut (2012)

<h3>Introduction</h3> There is a documented association between low Vitamin D levels and IBD. In addition to the metabolic effects of Vitamin D it also has an immunomodulatory role which includes inhibition of the Th1 response (IL-2, IL-10 and TNF-α). Vitamin D deficiency may be an effect of the inflammatory process resulting in malabsorption of Vitamin D from the gastrointestinal tract or a propagating factor in IBD through loss of Th1 suppression. Vitamin D deficiency may affect the response of IBD patients to biologic drugs that act through the same immunological pathway. The primary aim of this study was to determine the prevalence of Vitamin D deficiency in a cohort of IBD patients currently receiving biologic therapy and investigate whether levels were associated with disease activity as determined by the GI inflammatory marker, faecal calprotectin. The secondary aim was to determine if Vitamin D level was associated with the following parameters: treatment group, corresponding serum CRP, history of small bowel Crohn9s, small bowel resection. <h3>Methods</h3> Patients receiving infliximab or adalimumab therapy for IBD at Glasgow Royal Infirmary between 1 June and 31 July 2011 were included in this retrospective cohort study (n=113). The following patient information was extracted from the NHS Greater Glasgow and Clyde Clinical Portal Database: treatment regime, start date, underlying GI diagnosis, GI surgical history, previous biologic therapy, Vitamin D level (serum 25OHD) and corresponding serum CRP and faecal calprotectin. <h3>Results</h3> 60 patients (53.1%) had a recorded Vitamin D level. Of these, 63.4% (n=38) were Vitamin D deficient (25 OHD &lt;50 nmol/l); 21.4% (n=13) were severely Vitamin D deficient (25 OHD &lt;25 nmol/l). The median Vitamin D level of the active disease group (faecal calprotectin &gt;200 μg/g) was 41 nmol/l (range: &lt;14–122 nmol/l) vs 39 nmol/l (range: 17–108 nmol/l) in the remission disease group (faecal calprotectin &lt;200 μg/g), p=0.63. There were no significant associations between Vitamin D level and biologic treatment group (p=0.65), small bowel resection (p=0.62), history of small bowel Crohn9s (p=0.42), and corresponding serum CRP (p=0.33). <h3>Conclusion</h3> Significant Vitamin D deficiency is common in our cohort of IBD patients receiving anti-TNFα therapy. Vitamin D level appears to be independent of disease activity and other specified parameters. There is evidence to consider the routine measurement of Vitamin D levels in IBD patients receiving biologic therapy and appropriate treatment of Vitamin D deficiency. <h3>Competing interests</h3> None declared.